FRAtnow

Fratnow is a biotechnology company specializing in the development of high-sensitivity diagnostic assays for Friedreich's Ataxia (FRDA). The company's core technology, the FRAtnow assay, utilizes liquid chromatography-mass spectrometry (LC-MS) to accurately quantify frataxin protein levels in whole blood and dried blood spots. This tool serves as a critical biomarker for clinical trials, allowing researchers to monitor the efficacy of frataxin-restoring therapies with greater precision than traditional ELISA methods. By providing a robust and validated measurement of frataxin, Fratnow supports the development of novel treatments for this rare neurodegenerative disease.